Table of contents
Expand All Topics
Vascular cognitive impairment
Guidelines
Key sources
The following summarized guidelines for the evaluation and management of vascular cognitive impairment are prepared by our editorial team based on guidelines from the European Society for Vascular Surgery (ESVS 2023), the Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD 2020), the European Federation of Neurological Societies (EFNS 2012), and the American Heart Association (AHA/ASA 2011).
1
2
3
4
Screening and diagnosis
Diagnostic procedures
Skin or muscle biopsy: as per AHA/ASA 2011 guidelines, consider obtaining an ultrastructural examination of the skin or muscle biopsy specimen for granular osmiophilic deposits as an alternative or complementary procedure if genetic testing is either unavailable or demonstrates NOTCH3 mutations of unclear significance.
C
Medical management
Management of cardiovascular risk factors
As per CCCDTD 2020 guidelines:
Consider initiating antihypertensive therapy for average DBP readings ≥ 90 mmHg and for average SBP readings ≥ 140 mmHg in patients with cognitive disorders if a vascular contribution is known or suspected.
B
Initiate guideline-recommended treatments to prevent first-ever or recurrent stroke as appropriate in all patients with cognitive symptoms or impairment.
B
More topics in this section
Cholinesterase inhibitors
NMDA antagonists
Antiplatelet therapy
Immunosuppressive therapy
Nonpharmacologic interventions
Preventative measures
Primary prevention, lifestyle modifications: as per AHA/ASA 2011 guidelines, consider advising moderation of alcohol intake, weight control, physical activity, a Mediterranean-type dietary pattern,
C
and smoking cessation in patients at risk for VCI. B
More topics in this section
Primary prevention (cardiovascular conditions)
Primary prevention (carotid interventions)